Recent studies of the AML molecular landscape at the genome and transcriptome levels highlighted the clinical significance of mutation in numerous genes, e.g., WT1, FLT3-ITD (mutation in the tyrosine kinase domain), IDH1, IDH2, KMT2A, NPM1, NUP98-NSD1, ASXL1, RUNX1, TP53, and DNMT3A [4,5]. Here, TP53 is linked to acute myeloid leukemia.